CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Prime Medicine, Inc.

PRME
$597MSmall Cap

Next catalyst

No upcoming catalyst in our data

No upcoming FDA decision, filing or trial readout is on file for PRME. That does not mean none is planned.

Get an email about PRME's next catalysts

Track Prime Medicine (PRME) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Catalyst Timeline

0 upcoming, 4 past

No catalysts found.

Market Overview

Stock performance and key metrics

NASDAQBiological Products, (No Diagnostic Substances)BiotechnologyπŸ‡ΊπŸ‡ΈNorth AmericaCAMBRIDGE214 employees

Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.

Website
Drug Pipeline

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

What is in Prime Medicine, Inc.'s drug pipeline?β†’

CatalystAlert tracks 2 drug candidates in Prime Medicine, Inc.'s (PRME) pipeline across Phase 2. Its lead program is PM359 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Prime Medicine, Inc.'s next FDA catalyst?β†’

CatalystAlert tracks every upcoming catalyst for Prime Medicine, Inc. (PRME) β€” PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β€” each confidence-rated as confirmed, estimated or AI-detected.

How do I track PRME biotech catalysts?β†’

Add PRME to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Prime Medicine, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply